Pharmaceutical
Zhejiang DTRM Biopharma LLC is a clinical stage biopharma company focusing on the development of patent-protected innovative therapies for cancer patients with unmet medical needs. Its office location is at 610 West Germantown Pike, Suite 205, Plymouth Meeting, PA 19462.
The simultaneous on-going clinical trials sponsored by DTRM Biopharma at University of Pennsylvania, Yale University, Duke University, Mayo Clinic Minnesota, Mayo Clinic Florida, Mayo Clinic Arizona, and Peking University Cancer Hospital in China include clinically differentiated BTK inhibitor DTRMWXHS-12, or its oral double therapy DTRM-505 and oral triplet therapy DTRM-555.
More than 8 patents have been granted in the U.S., China, and other PCT Countries/Regions.
The pursuit of developing precision medicines globally is funded through a seed money of $12 million and a Series A of USD61 million (total $73 million) since November 11, 2011.